16304-39-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxybenzo[b]thiophene-3-carboxylic acid is used as a reactant in the synthesis of derivatives of prostaglandin D2 receptor antagonists with a 6,6-dimethylbicyclo[3.1.1]heptane skeleton. These derivatives have potential applications in the development of antiallergic drugs, as they can help modulate the immune response and alleviate allergic symptoms.
Additionally, due to its chemical structure, 5-hydroxybenzo[b]thiophene-3-carboxylic acid may also be utilized in the synthesis of other bioactive compounds, contributing to the advancement of pharmaceutical research and drug development.

Upstream product

• 90920-99-3 methyl 5-hydroxybenzo[b]thiophene-3-carboxylate 
• 4923-87-9 5-bromobenzo[b]thiophene 
• 1423-63-8 1-(5-bromobenzo[b]thiophen-3-yl)ethan-1-one 
• 106-53-6 para-bromobenzenethiol 
• 209268-25-7 5-benzenesulfonyloxybenzo[b]thiophene-3-carboxylic acid 
• 7312-24-5 5-bromobenzo[b]thiophene-3-carboxylic acid 
• 123392-43-8 5-methoxy-3-benzo[b]thiophenecarboxylic acid 
• 118780-12-4 1-bromo-4-[2,2-(dimethoxy)ethylsulfanyl]benzene 

Downstream Products

• 209268-27-9 5-benzenesulfonyloxybenzo[b]thiophene-3-carbonyl chloride 

Relevant academic research and scientific papers

Process for the preparation of pgd2 antagonist

The present invention provides an efficient process for the preparation of benzothiophenecarboxamide PGD2 antagonist, S-5751.

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-dimethylbicyclo[3.1.1]heptane derivatives

In an earlier paper, we reported that novel prostaglandin D2 (PGD2) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD2 receptor antagonists having the 6,6-dimethylbicyclo [3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD2 receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.

Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives

Processes for producing compounds of the formula (VI) are disclosed. Benzothiophenecarboxylic acid derivatives of the formula (I), which are useful as starting materials for producing drugs, are disclosed. Particularly, disclosed is a process for preparin

Process for producing 5-hydroxybenzo[b] thiophene-3-carboxylic acid derivatives

Benzothiophenecarboxylic acid derivatives of the formula (I) which are useful as starting materials for producing drugs, and a process for preparing 5-hydroxybenzo[b]-thiophene-3-carboxylic acid derivatives of the formula (VI) which are specific PGD2

Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them

PCT No. PCT/JP97/04527 Sec. 371 Date May 17, 1999 Sec. 102(e) Date May 17, 1999 PCT Filed Dec. 10, 1997 PCT Pub. No. WO98/25919 PCT Pub. Date Jun. 18, 1998A compound, a pharmaceutically acceptable salt thereof, or a hydrate thereof having PGD2-antagonisti